Rigel Pharma (RIGL) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Rigel Pharmaceuticals (RIGL) PT Raised to $10 at BMO Capital Following Q1 Earnings Beat
May 2, 2018 1:12 AM EDTBMO Capital raised its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $10.00 (from $8.00) while maintaining a Outperform rating.
Analyst Do Kim comments "We raise our estimates and target price to $10 from $8, as Rigel sets Tavalisse monthly WAC price at $9,450 or $113,400 annually,... More
